A little perspective
I am new to the board but it has been fun reading the posts
Here are some additional facts that I uncovered which you may wish to consider
Feb 2010 (don’t know where they sit today) BPAX was ranked 15th out of 67 biotech companies for the quality of their patent portfolio. I have attached the top 10 listed on the Patent Scorecard as published by The Patent Board.
1 Roche Holding Ltd
2 Johnson & Johnson
3 Amgen Inc
4 Biogen Idec
5 Isis Pharmaceuticals
6 Merck KGaA
7 Bristol-Myers Squibb
8 Human Genome Sciences
9 Alnylam Pharmaceuticals
10 Sanofi
With respect to the a/n Biotechnology top 10 in patent quality only Isis Pharmaceuticals ($719 million Market Value & -$.079 EPS ) and Alnylam Pharmaceuticals ($351 million Market Value & -$1.18 EPS ) have a sub $1 billion market value. A quick look at product development and pipelines, it appears to me that solely based on these factors (Libigel aside) the market value should sit somewhere between the two, as BPAX appears to have a more developed portfolio with Phase 3 trials and approvals then Alnylam Pharmaceuticals. Yet, BPAX today only has a market value of $56 million and an EPS of -$0.69
BPAX has equity stake in external companies
19.9 % ownership of Cold Genesis (Private Company) who are presently conducting phase II and III trials
Transitional Cell Carcinoma Biological: CG0070 adenovirus vector
Phase II
Bladder Cancer Other: Control Arm: Triple Choice Phase III
16 % ownership of Ceregene, Inc. (Private Company) who have the following pipeline
Pakinsinson Deaease Phase II trials
Alzhiener's Disease Phase II trials
This is all in addition to Biosante’s pipleine Elestrin (approved) Libigel, Bio-T-Gel, The Pill Plus.
Cancer research is expensive however BPAX has found a way to partner and entice other companies to further their research (i.e., GVAX) Some complain about not getting much in return for allowing the use of their vaccines. I believe practically giving it way will prove fruitful in the end. More partners playing with their vaccines will speed up it’s time to market while reducing associated costs. Monetizing came later for Facebook the same could happen with BPAX.
In all this is not a one product wonder,by all accounts it looks like BPAX wants to play with the big boys or girls. The best $56 million company I have ever seen.
